Patients with von Hippel–Lindau disease, a genetic condition brought on by a mutation in the VHL gene that predisposes the carrier to developing different kinds of tumors, have a high incidence of cancers, like kidney cancer. This is because of an inactive VHL gene that leads to hypoxia signaling, a condition that results from an imbalance...
Tag: <span>Hippel-Lindau disease</span>
Post
Belzutifan induced strong responses in patients with von Hippel-Lindau disease-associated kidney cancer
HOUSTON ― Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong clinical activity in patients with renal cell carcinomas (RCC) and non-renal cell carcinoma neoplasms associated with von Hippel-Lindau (VHL) disease. The study was published...